This company is no longer active
Selectimmune Pharma Past Earnings Performance
Past criteria checks 0/6
Selectimmune Pharma's earnings have been declining at an average annual rate of -22.5%, while the Pharmaceuticals industry saw earnings growing at 13.7% annually.
Key information
-22.5%
Earnings growth rate
-21.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | n/a |
| Return on equity | -141.7% |
| Net Margin | n/a |
| Next Earnings Update | 29 Aug 2023 |
Revenue & Expenses BreakdownBeta
How Selectimmune Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -9 | 8 | 0 |
| 31 Dec 22 | 0 | -9 | 9 | 0 |
| 30 Sep 22 | 0 | -12 | 12 | 0 |
| 30 Jun 22 | 0 | -14 | 14 | 0 |
| 31 Mar 22 | 0 | -16 | 16 | 0 |
| 31 Dec 21 | 0 | -15 | 15 | 0 |
| 30 Sep 21 | 0 | -14 | 13 | 0 |
| 30 Jun 21 | 0 | -13 | 12 | 0 |
| 31 Mar 21 | 0 | -9 | 8 | 0 |
| 31 Dec 20 | 0 | -9 | 9 | 0 |
| 30 Sep 20 | 0 | -8 | 8 | 0 |
| 30 Jun 20 | 0 | -8 | 8 | 0 |
| 31 Mar 20 | 0 | -10 | 10 | 0 |
| 31 Dec 19 | 0 | -9 | 9 | 0 |
| 30 Jun 19 | 0 | -4 | 4 | 0 |
Quality Earnings: SELECT B is currently unprofitable.
Growing Profit Margin: SELECT B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SELECT B is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare SELECT B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SELECT B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.8%).
Return on Equity
High ROE: SELECT B has a negative Return on Equity (-141.66%), as it is currently unprofitable.